TRB induced the overexpression of PD-1 in vivo but it did not in vitro, and Chiara Ratti et al. proved that TRB + anti-PD-1 blocking antibody increased CD8+ infiltrating cells and TRB efficacy, whereas anti-PD-1 alone did not reduce osteosarcoma growth. Here, CD8A is linked to osteosarcoma.